CD38


Also found in: Acronyms, Wikipedia.

CD38

a transmembrane protein present on macrophages, dendritic cells, and activated cells of the natural killer, B-cell and T-cell lines that can facilitate B-cell adhesion.
References in periodicals archive ?
CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFN[eth][thorn] Cytokines and Proliferation.
In all cases the plasma cells were strongly positive for CD38, CD138, and monotypic immunoglobulin light chain ([kappa] in 18, [lambda] in 10).
Normal plasma cells are polyclonal and exhibit high-level CD38 and CD19, and variable CD45 expression, but no CD56 expression.
CD38 expression on CD8(+) T cells as a prognostic marker in vertically HIV-infected pediatric patients.
0 (Graph-Pad Software) to determine the ZAP70, LPL, and CD38 expression cutoff values that best distinguished mutated and unmutated cases.
Recent studies by our group and others have shown that a large proportion of FoxP3-expressing CD4+ T cells also co-express markers of immune activation (HLA-DR, CD38, Ki-67, PD-1), and that these cells are most common in patients with untreated disease [42,43,49].
FITC PE PE-Cy5 APC 1 [kappa] CD34 CD62L CD38 2 [kappa] CD14 CD44 CD38 3 [kappa] CD126 HLA-DR CD38 4 [kappa] CD117 CD128 CD38 5 [kappa] CD11b CD38 CD3 6 [kappa] CD184 CD38 CD19 7 [kappa] CD45ro CD38 CD10 8 [kappa] CD31 CD38 CD54 9 [kappa] CD50 CD38 CD49d 10 [kappa] CD130 CD38 CD44 11 [kappa] CD56 CD38 CD20 12 [lambda] CD34 CD62L CD38 13 [lambda] CD14 CD44 CD38 14 [lambda] CD126 HLA-DR CD38 15 [lambda] CD117 CD128 CD38 16 [lambda] CD11b CD38 CD3 17 [lambda] CD184 CD38 CD19 18 [lambda] CD45ro CD38 CD10 19 [lambda] CD31 CD38 CD54 20 [lambda] CD50 CD38 CD49d 21 [lambda] CD130 CD38 CD44 22 [lambda] CD56 CD38 CD20 Abbreviations: APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PE-Cy5, phycoerythrin-Cy5.
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B cell chronic lymphocytic leukemia.
At day 28, the percentage of CD4+ and CD8+ T cells expressing the activation markers CD38 and HLA-DR had decreased 28.
Cellectis is currently developing three proprietary allogeneic CAR T-cell product candidates in the field of liquid tumors, targeting CD123 in acute myeloid leukemia, as well as CD38 and CS1 for multiple myeloma.
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.